Sarepta Therapeutics (SRPT) Tops Q2 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics (SRPT) PT Raised to $33 at Morgan Stanley
July 20, 2017 9:16 AM EDTMorgan Stanley raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $33.00 (from $31.00) while maintaining a Equalweight rating.
... MoreSarepta Therapeutics (SRPT) PT Raised to $69 at Cowen Following 'Beat and Raise'
July 20, 2017 6:07 AM EDTCowen analyst Ritu Baral raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $69.00 (from $62.00) while maintaining a Outperform rating following a solid beat and raise for Exondys 51 revenues.
Baral sees continued progress with both prescribers and payors... More
